The Perfect Child Sued by Elevance Health over $800M in Fraudulent Billing

Elevance Health (NYSE: ELV) sued The Perfect Child ABA and its founder, alleging $800M in fraudulent billing since 2021. The suit claims deceptive practices, inflated prices, and threats to patients' families. Elevance Health paid $160M to The Perfect Child ABA. The company is also facing a federal lawsuit by a parent for $363,816.17 in alleged surprise billing.

Original reporting
Published Nov 6, 2026, 8:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 8:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
The Perfect Child Sued by Elevance Health over $800M in Fraudulent Billing — source image
Decision brief

The 30-second read

$ELVBearishMed
01

Why it matters

The lawsuit could lead to significant financial charges, increased regulatory scrutiny, and reputational damage for Elevance Health.

02

Market read

The case introduces material legal risk for Elevance Health, likely pressuring its stock and prompting sector‑wide attention to billing practices.

03

What to watch

Potential insurance recoveries, the outcome of related FBI investigation, and any insurance reserve adjustments.

Relevance 7/10Novelty 8/10Timing: immediate

Background

Elevance Health (NYSE: ELV) sued The Perfect Child ABA and its founder for alleged out‑of‑network fraudulent billing totaling $800M since 2021.

Company-level read

Ticker impact

$ELVBearishHigh confidence
Context

Elevance Health filed a lawsuit alleging $800M fraudulent billing by The Perfect Child ABA and its network.

Expected impact

downward pressure as investors price in potential liabilities and reputational damage

Evidence & confidence

Large-scale fraud allegations ($800M) are material and likely to affect earnings and stock perception immediately.

Market effects

Highlights heightened scrutiny on health‑plan billing practices, potentially affecting other insurers.

U.S. health‑insurance sector may see modest sell‑off.

Limited to U.S. insurers; no direct global impact.

Counterpoint

If Elevance Health can recover the $800M through insurance recoveries or settlements, the impact may be muted.

Key entities

  • Elevance Health

    U.S. health insurer filing the lawsuit.

  • The Perfect Child ABA

    Defendant accused of fraudulent billing.

Related articles

$CNCMed

Health insurers, hospitals rally after sweeping midterm win for Democrats

Shares of Medicaid-focused health insurers (Centene, Elevance, Molina) and hospital operators (HCA, Tenet, Universal) rose after Democrats won the midterms, raising hopes for sector-friendly policies. Analysts expect delays in Trump's OBBBA, easing pressure on Medicaid and ACA insurers, and potential extensions of enhanced subsidies. Year-to-date gains vary among companies.

$CVSMed

Aetna, Elevance, and Four Other Insurers Say the Medicare Advantage Star Rating System Is Broken — Now They Are Suing

CVS Health's Aetna subsidiary, along with Elevance Health, SCAN Health Plan, Alignment Healthcare, Healthfirst, and Centene, sued CMS over Medicare Advantage star ratings. They allege CMS used invalid measures, leading to lower ratings and $2B+ in lost bonus payments for Aetna. CMS has not responded. Ratings affect benefits for 4.2M Aetna members and $12.7B in annual bonuses.

Med

Elevance Earns $1.4 Billion Quarterly Profit as Membership Falls by 487,000 and Insurer Calls 2026 the Medicaid Trough

Elevance Health reported a $1.4B Q3 profit, up from $1.2B a year earlier, with 44.9M members, down 487K. The company expects 2026 to be the low point for Medicaid margins, with improvement in 2027. Elevance raised its full-year outlook to at least $29 per share, but is exiting some Medicaid markets and tightening spending. Medicaid work requirements begin in January 2027, potentially affecting 2.3M people.

$ELVMed

BofA raises Elevance stock price target to $500 on earnings beat

BofA Securities raised its price target for Elevance Health (ELV) to $500 from $480, citing a 10% Q3 earnings beat and raised 2026 guidance. The company's market cap is $94.2B, P/E ratio 19.62. BofA highlights seven 2027 tailwinds, including margin improvements and share buybacks. ELV reported Q3 EPS of $6.99 vs. $4.70 estimate, revenue of $50.4B vs. $49.32B estimate.